Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

被引：10
作者：
Switzer, Benjamin [1 ]
Haanen, John [2 ]
Lorigan, Paul C. [3 ,4 ]
Puzanov, Igor [1 ]
Turajlic, Samra [5 ,6 ,7 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY 14203 USA
[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands
[3] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[4] Christie NHS Fdn Trust, Div Med Oncol, Manchester, Lancs, England
[5] Royal Marsden NHS Fdn Trust, Renal Unit, London, England
[6] Royal Marsden NHS Fdn Trust, Skin Unit, London, England
[7] Francis Crick Inst, Canc Dynam Lab, London, England
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 07期
基金：
英国惠康基金; 英国医学研究理事会;
关键词：
immunotherapy; COVID-19; melanoma; kidney neoplasms; vaccination; CANCER-PATIENTS; SUPPRESSOR-CELLS; VIRUS-INFECTION; MYELOID CELLS; T-CELLS; INFLAMMATION; VACCINE; INNATE; IMMUNOPATHOLOGY; IMMUNOTHERAPY;
D O I：
10.1136/jitc-2021-002835
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.
引用
收藏
页数：10
相关论文
共 50 条
  • [41] Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors
    Bonnefin, C.
    Schneider, S.
    Gerard, E.
    Dutriaux, C.
    Ferte, T.
    Prey, S.
    Guicheney, M.
    Ducharme, O.
    Pedeboscq, S.
    Beylot-Barry, M.
    Pham-Ledard, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
  • [42] COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy
    da Costa, Cesar Martins
    de Souza, Zenaide Silva
    Real Salgues, Alessandra Corte
    Harada, Guilherme
    Marino Rodrigues Ayres, Pedro Paulo
    Vieira Nunes, Daniela Bulhoes
    Katz, Artur
    Munhoz, Rodrigo Ramella
    IMMUNOTHERAPY, 2020, 12 (15) : 1133 - 1138
  • [43] Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
    Vivarelli, Silvia
    Falzone, Luca
    Grillo, Caterina Maria
    Scandurra, Giuseppa
    Torino, Francesco
    Libra, Massimo
    CANCERS, 2020, 12 (08) : 1 - 22
  • [44] Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
    Kevin Tyan
    Joanna Baginska
    Martha Brainard
    Anita Giobbie-Hurder
    Mariano Severgnini
    Michael Manos
    Rizwan Haq
    Elizabeth I. Buchbinder
    Patrick A. Ott
    F. Stephen Hodi
    Osama E. Rahma
    Cancer Immunology, Immunotherapy, 2021, 70 : 2209 - 2221
  • [45] Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
    Patel, Viral
    Elias, Roy
    Formella, Joseph
    Schwartzman, William
    Christie, Alana
    Cai, Qi
    Malladi, Venkat
    Kapur, Payal
    Vazquez, Miguel
    McKay, Renee
    Pedrosa, Ivan
    Hannan, Raquibul
    Hammers, Hans
    Brugarolas, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [46] A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
    Yu, Eun-mi
    Linville, Laura
    Rosenthal, Matthew
    Aragon-Ching, Jeanny B.
    VACCINES, 2021, 9 (08)
  • [47] Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
    Tyan, Kevin
    Baginska, Joanna
    Brainard, Martha
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Manos, Michael
    Haq, Rizwan
    Buchbinder, Elizabeth I.
    Ott, Patrick A.
    Hodi, F. Stephen
    Rahma, Osama E.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2209 - 2221
  • [48] Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Masson, Claire
    Thouvenin, Jonathan
    Boudier, Philippe
    Maillet, Denis
    Kuchler-Bopp, Sabine
    Barthelemy, Philippe
    Massfelder, Thierry
    CANCERS, 2023, 15 (12)
  • [49] Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors
    Adhikari, Arjab
    Sapkota, Supriya
    Gogia, Sopiko
    Ojbindra, K. C.
    CANCER EPIDEMIOLOGY, 2024, 92
  • [50] Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
    Rouhani, Sherin Juliet
    Yu, Jovian
    Olson, Daniel
    Zha, Yuanyuan
    Pezeshk, Apameh
    Cabanov, Alexandra
    Pyzer, Athalia R.
    Trujillo, Jonathan
    Derman, Benjamin A.
    O'Donnell, Peter
    Jakubowiak, Andrzej
    Kindler, Hedy L.
    Bestvina, Christine
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
12345